NASDAQ$AUTL
Autolus Therapeu · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Autolus reported its Q3 2024 financial results and business updates.
Autolus Therapeutics reported a net loss of $82.1 million for the third quarter ended September 30, 2024. The FDA approved AUCATZYL, triggering a $30 million milestone payment from Blackstone. The company's cash and cash equivalents totaled $657.1 million.
- AUCATZYL (obecabtagene autoleucel) was approved by the US FDA on November 8, 2024.
- BLA approval triggered a $30 million milestone payment to Autolus from Blackstone.
- Matthias Will M.D. was appointed as Chief Development Officer, effective September 30, 2024.
- Obe-cel is under regulatory review in both the EU and the UK.
Headline financials
Revenue & EPS history
Autolus · Revenue · Quarterly
$63K
Revenue by segment
Autolus · $26.2M total across 1 segment · Q1 2026
- AUCATZYL$26.2M—100.0%
Forward guidance
Autolus anticipates several milestones in the near term. Obe-cel FELIX data will be presented at the American Society of Hematology (ASH) meeting in December 2024. Initial data from the SLE Phase 1 study is expected in Q1 2025 and initial data from the PY01 trial of obe-cel in pediatric ALL is expected in H2 2025.
Tailwinds
- Obe-cel FELIX data at American Society of Hematology (ASH) meeting December 2024
- Obe-cel in autoimmune disease – initial data from SLE Phase 1 study Q1 2025
- Initial data from PY01 trial of obe-cel in pediatric ALL H2 2025
- SLE Phase 1 trial presentation at medical conference H2 2025
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2024
-1.5%
Avg return
Earnings day
-4.3%
Avg return
5 days after
+0.7%
Avg return
30 days after
38%
12 / 32 earnings
Positive
+38.6%
Q3 2023
Best reaction
-23.6%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -1.4% | -8.5% | — | |
| Q1 2026 | -7.6% | -5.3% | -8.8% | |
| Q3 2025 | -10.7% | -10.7% | +7.3% | |
| Q2 2025 | -12.7% | -27.9% | -42.1% | |
| Q1 2025 | +10.0% | +3.3% | +90.2% | |
| Q4 2024 | -13.4% | -16.5% | -26.3% | |
| Q3 2024 | -6.3% | -12.3% | -23.4% | |
| Q2 2024 | -8.7% | -6.7% | -0.4% | |
| Q1 2024 | -1.2% | -5.7% | +10.6% | |
| Q4 2023 | +6.2% | +13.1% | -8.4% | |
| Q3 2023 | +38.6% | +24.7% | +42.0% | |
| Q2 2023 | -3.5% | -5.1% | +6.7% | |
| Q1 2023 | -3.6% | -1.5% | +48.0% | |
| Q4 2022 | +6.8% | -0.5% | -4.7% | |
| Q3 2022 | -15.6% | -25.9% | +7.2% | |
| Q2 2022 | +24.7% | +18.3% | +14.0% | |
| Q1 2022 | -11.5% | -19.0% | -15.6% | |
| Q4 2021 | +3.6% | +1.8% | +15.9% | |
| Q3 2021 | +2.0% | +25.8% | +4.0% | |
| Q2 2021 | +5.2% | +4.9% | +26.0% | |
| Q1 2021 | +3.3% | -4.0% | +22.1% | |
| Q4 2020 | -3.4% | -1.1% | -7.8% | |
| Q3 2020 | -8.3% | -7.9% | -12.1% | |
| Q2 2020 | +4.2% | +2.3% | -17.8% | |
| Q1 2020 | -1.8% | +1.6% | +27.8% | |
| Q4 2019 | +10.6% | -1.8% | -35.4% | |
| Q3 2019 | -7.6% | -11.8% | +13.0% | |
| Q2 2019 | -23.6% | -32.4% | -5.0% | |
| Q1 2019 | +6.7% | +0.9% | -28.3% | |
| Q4 2018 | -6.5% | -4.3% | -4.0% | |
| Q3 2018 | -10.6% | -12.6% | -36.3% | |
| Q2 2018 | -10.6% | -12.6% | -36.3% | |
| Q1 2018 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro